BMI as a modifier of Janus kinase inhibitor response in rheumatoid arthritis

The Lancet Rheumatology · Published 2026-08-01 · DOI 10.1016/s2665-9913(26)00209-2

Authors (2)

Chary Lopez Pedrera, Carlos Perez Sanchez

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Pedrera, C., Sanchez, C. (2026). BMI as a modifier of Janus kinase inhibitor response in rheumatoid arthritis. The Lancet Rheumatology. https://doi.org/10.1016/s2665-9913(26)00209-2

Related articles

• Redefining axial spondyloarthritis: more than just back pain · The Lancet Rheumatology · 2026 · Same journal
• Anti-MDA5-associated rapidly progressive-ILD—the intersection of hyperinflammation and fibrosis · The Lancet Rheumatology · 2026 · Same journal
• Infection risk in adults with secondary HLH · The Lancet Rheumatology · 2026 · Same journal
• The at-risk-to-early continuum of enteropathic spondyloarthritis · The Lancet Rheumatology · 2026 · Same journal
• Prevalence and determinants of sacroiliac joint bone marrow oedema in the general population in Germany: a population-based cross-sectional study · The Lancet Rheumatology · 2026 · Same journal
• Detection of GLP-1 and DPP-4 in synovial fluid: implications for therapeutical strategies in arthritis · The Lancet Rheumatology · 2026 · Same journal
• Prediction of psoriatic arthritis risk: watch for symptoms · The Lancet Rheumatology · 2026 · Same journal
• Lifestyle factors in difficult-to-treat rheumatoid arthritis · The Lancet Rheumatology · 2026 · Same journal
• Research in Brief · The Lancet Rheumatology · 2026 · Same journal
• Gout treat-to-target for whom? · The Lancet Rheumatology · 2026 · Same journal